Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Something big is likely in the works

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Jan 08, 2022 8:58pm

215 Views

Post# 34296958

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Something big is likely in the works

Let's see what the phase 1a results are first. If they show efficacy then the stock might rise considerably in the months ahead leading to the offering. Then again, there may be cash flowing to TH from partnerships so that may obviate the need for an offering.

jeffm34 wrote: On the other hand, underwhelming results will tank the stock price. Most prudent companies wouldn't take that risk. Unfortunately the timing for another financing is most likely before cancer results come out, unless you are 100% certain of the outcome of the cancer trial.

SPCEO1 wrote: We should know about efficacy in about 6-8 months with the phase 1b trial and, if that trial is successful in multiple cancer types, the valuation of TH is going to skyrocket.